Please assess the completion status of the following clinical trial:

Trial Title: Brexpiprazole in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has completed the lead-in study 14644A.~* The patient is judged to potentially benefit from 52-week treatment with brexpiprazole according to the clinical opinion of the investigator.~* The patient agrees to protocol-defined use of effective contraception.~Exclusion Criteria:~* The patient has been diagnosed with a primary psychiatric disorder other than schizophrenia during Study 14644A.~* The patient has a clinically significant unstable illness diagnosed during Study 14644A.~* The patient, in the opinion of the investigator or according to Columbia-Suicide Severity Rating Scale (C-SSRS), is at significant risk of suicide.~* The patient has an abnormal ECG or other abnormal ECG tests that are, in the investigator's opinion, clinically significant.~* The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.~Other inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).